论文部分内容阅读
目的:研究恩格列净对2型糖尿病（T2DM）患者超声心动图左心功能相关指标及糖尿病相关生化指标水平变化的影响。方法:选取2020年12月至2021年5月于天津医科大学朱宪彝纪念医院就诊的120例T2DM合并心脏功能损害患者，采用随机数字表法随机分为对照组（n n=60）和观察组（n n=60）。对照组仍采用原有降糖方案，观察组在原治疗基础上加服恩格列净。最终剔除6例，完成114例，每组57例。分别于治疗前后观察两组患者超声心动图左心功能相关指标[n E/n e\'、左房容积指数（LAVI）、三尖瓣反流速度、左心室射血分数（LVEF）]及实验室指标[空腹血糖（FBG）、糖化血红蛋白（HbA1c）、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）]水平的变化。n 结果:治疗后观察组的n E/n e\'和LAVI较治疗前及对照组均有所下降，差异均具有统计学意义（均n P0.05）；治疗后两组的FBG和HbA1c水平较治疗前均有所下降，但两组间差异均无统计学意义（均n P>0.05）。n 结论:恩格列净能有效改善T2DM患者的n E/n e\'和LAVI，但对三尖瓣反流速度、LVEF及血脂等指标改善不明显，其能早期且显著改善左心室舒张功能，从而对患者治疗具有积极作用，且安全性高、不良反应少，值得临床推广。n “,”Objective:To study the effects of Empagliflozin on left ventricular function and the level of blood glucose and lipid in type 2 diabetes mellitus (T2DM) patients.Methods:A total of 120 patients with T2DM complicated with cardiac function impairment were selected from Chu Hsien-I Memorial Hospital, Tianjin Medical University from December 2020 to May 2021. The diabetic patients were randomly divided into the observation group (60 cases) and control group (60 cases) by random number table method. Patients in the observation group were treated with Empagliflozin, while the control group underwent original hypoglycemic treatment. After the treatment, 6 cases were eliminated and 114 cases were completed, with 57 cases in each group. The changes of echocardiographic left ventricular function related indexes such as n E/n e\', left atrial volume index (LAVI), tricuspid regurgitation speed, left ventricular ejection fraction (LVEF) and laboratory indexes in the two groups were observed before and after treatment. The laboratory indexes checked include fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL) and how density lipoprotein (HDL).n Results:The n E/n e\', LAVI of the observation groups was significantly lower than that of the control group, and the differences were statistically significant (alln P0.05). After the treatment, the levels of FBG and HbA1c in the two groups decreased, but there was no significant difference between the two groups (alln P>0.05).n Conclusions:Empagliflozin can effectively control the n E/n e\', LAVI of T2DM patients, and can early significant improvement of left ventricula diastolic function, which is very favorable for the patients. Along with good safety, Empagliflozin is suitable for clinical recommendation.n